Jenburkt Pharmaceuticals reports strong Q2 and half-year financial performance

Jenburkt Pharmaceuticals reported a robust financial performance for the quarter and half-year ended September 30, 2025. Revenue from operations for the quarter surged to INR 4555.76 Lacs, with total income reaching INR 4763.66 Lacs. Profit after tax for the quarter stood at INR 1016.34 Lacs, compared to INR 960.05 Lacs in the same quarter last year, reflecting a healthy growth trajectory. Basic and diluted earnings per share for the quarter were INR 23.03, up from INR 21.75 previously.

For the half-year, the company recorded a total income of INR 8522.05 Lacs, a notable increase from INR 7701.06 Lacs in the prior half-year period. Profit after tax for the six-month period climbed to INR 1795.52 Lacs, compared to INR 1701.65 Lacs in the corresponding period of 2024. This performance led to basic and diluted earnings per share of INR 40.68 for the half-year, an increase from INR 38.56 in the previous year.

The board of directors approved and adopted these unaudited standalone financial statements on October 28, 2025, following the recommendation of the audit committee. The company's total assets as of September 30, 2025, were INR 20906.79 Lacs, up from INR 19618.60 Lacs as of March 31, 2025.